European Journal of Pediatrics

, Volume 170, Issue 4, pp 493–501 | Cite as

Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas

  • Clemens Schiestl
  • Kathrin Neuhaus
  • Silke Zoller
  • Ulrike Subotic
  • Ishilde Forster-Kuebler
  • Rike Michels
  • Christian Balmer
  • Lisa Weibel
Original Paper

Abstract

Beta-blockers are a highly promising treatment modality for complicated infantile hemangiomas (IH). However, data on propranolol as first-line treatment, objective outcome measures and impact on hemodynamics in young infants is limited. We retrospectively evaluated a homogenous group of infants with proliferating complicated IH treated with propranolol (2 mg/kg/day). Outcome was assessed by blinded evaluation of clinical photographs by visual analogue scale (VAS), ultrasound examination and ophthalmological review (if appropriate). Tolerance and hemodynamic variables were recorded over time, including a 2-day in-patient observation at the initiation of therapy. Twenty-five infants (median age 3.6 (1.5–9.1) months) were included in the study. The median follow-up-time was 14 (9–20) months and 14 patients completed treatment at a median age of 14.3 (11.4–22.1) months, after a duration of 10.5 (7.5–16) months. In all patients, there was significant fading of colour (with a VAS of −9 (−6 to −9) after 7 months) and significant decrease in size of the IH (with a VAS of −8 (−3 to −10) after 7 months). Median thickness of the lesions assessed by ultrasound at baseline and after 1 month was 14 (7–28) mm and 10 (5–23) mm, respectively (p < 0.01). In children with periocular involvement, astigmatism and amblyopia resolved rapidly within 8 weeks. The overall tolerance of propranolol was good, and no relevant hemodynamic changes were noted. Conclusion: Our report supports the excellent effect and good tolerance of this novel therapy, and we propose the use of propranolol as first-line treatment for IH.

Keywords

Hemangioma Infantile Propranolol Children Betareceptor antagonist 

Notes

Acknowledgments

We thank Valérie Jaquet and Gabriela Acklin (Photographers, University Children’s Hospital) for performing the photographic documentation of this study. We gratefully acknowledge Dr. Stephan Nobbe (Dermatologist, University Hospital Zurich) for reviewing and scoring the patient’s photographs and Dr. Alain Rudiger (Internal Medicine, University Hospital Zurich) for his statistical advise.

Statement of all funding sources that supported the work: LW was supported by non-restricted grants from the Stiefel-Zangger Foundation and UBS Foundation of the University Children’s Hospital of Zurich.

Conflict of Interest

The study was sponsored by departmental funds. Dr. Lisa Weibel was supported by non-restricted grants from the Stiefel-Zangger Foundation and UBS Foundation of the University Children’s Hospital of Zurich. She also received honoraria for consulting activities from Laboratoires Pierre Fabre. LW has received honoraria for consulting activities for Laboratoires Pierre Fabre.

References

  1. 1.
    Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ (2001) Oral corticosteroid use is effective for cutaneous hemangiomas: an evicence-based evaluation. Arch Dermatol 137:1208–1213PubMedGoogle Scholar
  2. 2.
    Bruckner AL, Frieden IJ (2003) Hemangiomas of infancy. J Am Acad Dermatol 48:477–493PubMedCrossRefGoogle Scholar
  3. 3.
    Buckmiller LM, Munson PD, Dyamenahalli U et al (2010) Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope 120:676–681PubMedCrossRefGoogle Scholar
  4. 4.
    Garin EH, Araya CE (2009) Treatment of systemic hypertension in children and adolescents. Curr Opin Pediatr 21:600–604PubMedCrossRefGoogle Scholar
  5. 5.
    Haggstrom AN, Drolet BA, Baselga E et al (2006) Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 118:882–887PubMedCrossRefGoogle Scholar
  6. 6.
    Haggstrom AN, Drolet BA, Baselga E et al (2007) Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 150:291–294PubMedCrossRefGoogle Scholar
  7. 7.
    Holland KE, Frieden IJ, Frommelt PC et al (2010) Hypoglycaemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 146:775–778PubMedCrossRefGoogle Scholar
  8. 8.
    Kent AL, Kecskes Z, Shadbolt B, Falk MC (2007) Blood pressure in the first year of life in healthy infants born at term. Pediatr Nephrol 22:1743–1749PubMedCrossRefGoogle Scholar
  9. 9.
    Kilcline C, Frieden IJ (2008) Infantile hemangiomas: how common are they? a systematic review of the medical literature. Pediatr Dermatol 25:168–173PubMedCrossRefGoogle Scholar
  10. 10.
    Laforgia N, Milano A, De Leo E, Bonifazi E (2009) Hemangioma and propranolol. Some remarks at the end of treatment. Differences from corticosteroids. Eur J Pediat Dermatol 19:175–191Google Scholar
  11. 11.
    Lawley LP, Siegfried E, Todd JL (2009) Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 26:610–614PubMedCrossRefGoogle Scholar
  12. 12.
    Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649–2651PubMedCrossRefGoogle Scholar
  13. 13.
    Love JN, Sikka N (2004) Are 1–2 tablets dangerous? beta-blocker exposure in toddlers. J Emerg Med 26:309–314PubMedCrossRefGoogle Scholar
  14. 14.
    Manunza F, Syed S, Laguda B et al (2010) Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol 162:466–468PubMedCrossRefGoogle Scholar
  15. 15.
    Michaud AP, Baumann NM, Burke DK et al (2004) Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 114:1231–1236PubMedCrossRefGoogle Scholar
  16. 16.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRefGoogle Scholar
  17. 17.
    Qin ZP, Liu XJ, Li KL et al (2009) Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety. Zhonghua Yi Xue Za Zhi 89:3230–3234Google Scholar
  18. 18.
    Sans V, Dumas de la Roque E, Berge J et al (2009) Propranolol for severe infantile hemangiomas: follow up-report. Pediatrics 124:423–431CrossRefGoogle Scholar
  19. 19.
    Storch CH, Hoeger PH (2010) Propranolol for infantile haemangiomas—insights into the molecular mechanisms of action. Br J Dermatol 163:269–274PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Clemens Schiestl
    • 1
  • Kathrin Neuhaus
    • 1
  • Silke Zoller
    • 1
  • Ulrike Subotic
    • 1
  • Ishilde Forster-Kuebler
    • 2
  • Rike Michels
    • 3
  • Christian Balmer
    • 4
  • Lisa Weibel
    • 5
    • 6
  1. 1.Division of Plastic SurgeryUniversity Children’s Hospital ZurichZurichSwitzerland
  2. 2.Division of RadiologyUniversity Children’s Hospital ZurichZurichSwitzerland
  3. 3.Department of OphthalmologyUniversity Hospital ZurichZurichSwitzerland
  4. 4.Division of CardiologyUniversity Children’s Hospital ZurichZurichSwitzerland
  5. 5.Division of DermatologyUniversity Children’s Hospital ZurichZurichSwitzerland
  6. 6.Department of DermatologyUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations